📇 Rhumatologue · VANNES CEDEX · (56) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Disponibilité géographique
5 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
141.3 rhumatos / 100 000 hab. — département bien doté
4 publications sur 5 ans↗
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Influence scientifique
3
3 articles ont été cités au moins 3fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
68
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
11
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
2
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Yves Rocher (France)
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHBA SITE DE VANNES
20 BD GENERAL MAURICE GUILLAUDOT BP 70555, 56017 VANNES CEDEX
CHIC QUIMPER
14 AV YVES THEPOT, 29107 QUIMPER CEDEX
CENTRE D'ONCOLOGIE SAINT-YVES
LE TENENIO 11 RUE DU DOCTEUR JOSEPH AUDIC BP 39, 56001 VANNES CEDEX
POLYCLINIQUE DE KERIO
KERIO CS 80040, 56920 NOYAL PONTIVY
CHCB SITE KERIO
KERIO BP 23, 56920 NOYAL PONTIVY
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Medicine · 2020
Abstract O-(2-[18F]fluoroethyl)-l-tyrosine positron-emission tomography/computed tomography (18F-FET PET/CT) is well known in brain tumor management. Our study aimed to identify the prognostic value of 18F-FET PET/CT in high-grade gliomas (HGG) according the current 2016 World Health Organization (WHO) classification. Patients with histologically proven WHO 2016 HGG were prospectively included. A dynamic 18F-FET PET/CT was performed allowing to obtain 2 static PET frames (static frame 1: 20–40 minutes and static frame 2: 2–22 minutes). We analyzed static parameters (standard uptake value [SUV]max, SUVmean, SUVpeak, TBRmax, TBRmean, tumoral lesion glycolysis, and metabolic tumoral volume) for various isocontours (from 10% to 90%). PET parameters, clinical features, and molecular biomarkers were compared with progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analysis. Twenty-nine patients were included (grade III n = 3, grade IV n = 26). Mean PFS and OS were, respectively, 8.8 and 13.9 months. According to univariate analysis, SUVmean, SUVpeak, TBRmax, and TBRmean were significantly correlated with OS. In static 1 analysis, TBRmax seemed to be the best OS prognostic parameter (P = .004). In static 2 analysis, TBRmean was the best parameter (P = .01). In static 1 analysis, only SUVpeak was significant (P = .05) for PFS. Good performance status (PS < 2; P < .0001) and extent of resection (P = .019) identified the subgroup of patients with the best OS. Only TBRmax (P = .026) and extent of resection (P = .025) remained significant parameters in multivariate analysis. Our data suggested that high TBRmax seemed to be the most significant OS independent prognostic factor in patients with newly diagnosed HGG.
Therapeutic advances in medical oncology · 2024
Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor ( EGFR) mutations. The main objective of this study was to describe, in the real-world setting, these patients’ incidence, clinical, and tumoral characteristics. Methods: The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France. EGFR status was determined retrospectively when not available before surgery. Results: The study includes 1391 no squamous NSCLC patients from 16 centers; EGFR status was determined before surgery in 692 (49.7%) of the cases and conducted as part of the study for 699 (50.3%); 171 (12.3%) were EGFR mutated; median age: 70 (range: 36–88) years; female: 59.6%; never smokers: 75.7%; non-squamous histology 97.7%, programmed death ligand-1 expression 0%/1–49%/⩾50 in 60.5%/25.7%/13.8%, respectively. Surgery was predominantly lobectomy (81%) or segmentectomy (14.9%), with systematic lymph node dissection in 95.9%. Resection completeness was R0 for 97%. Post-surgery staging was as follows: IA: 52%, IB: 16%, IIA: 4%, IIB: 10%, IIIA: 16%, and IIIB: 0.05%; EGFR mutation exon was Del19/exon 21 ( L858R)/20/18 in 37.4%/36.8%/14%, and 6.4% of cases, respectively; 31 (18%) patients received adjuvant treatment (chemotherapy: 93%, EGFR tyrosine kinase inhibitor: 0%, radiotherapy: 20%). After a median follow-up of 31 (95% confidence interval: 29.6–33.1) months, 45 (26%) patients relapsed: 11/45 (24%) locally and 34 (76%) with metastatic progression. Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60%. Conclusion: This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical lung cancer · 2025 · Journal Article
Fave T, Nguyen J, Descourt R, Quéré G, et al.
Medicine · 2020 · Journal Article
Dissaux G, Basse V, Schick U, El Kabbaj O, et al.
Cancer management and research · 2019 · Journal Article
Vergnenègre A, Basse V, Le Garff G, Bylicki O, et al.
Therapeutic advances in medical oncology · 2024 · Journal Article
Auliac JB, Thomas PA, Bylicki O, Guisier F, et al.
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)
Background:Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor (<i>EGFR</i>) mutations. The main objective
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)
Background:Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor (<i>EGFR</i>) mutations. The main objective
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).